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Abstract
Background: Family therapy and family-based treatment has been commonly applied in children and adolescents
in mental health care and has been proven to be effective. There is an increased interest in economic evaluations
of these, often expensive, interventions. The aim of this systematic review is to summarize and evaluate the
evidence on cost-effectiveness of family/family-based therapy for externalizing disorders, substance use disorders
and delinquency.
Methods: A systematic literature search was performed in PubMed, Education Resource information Centre (ERIC),
Psycinfo and Cochrane reviews including studies conducted after 1990 and before the first of August of 2013.
Full economic evaluations investigating family/family-based interventions for adolescents between 10 and 20
years treated for substance use disorders, delinquency or externalizing disorders were included.
Results: Seven hundred thirty-one articles met the search criteria and 51 studies were initially selected.
The final selection resulted in the inclusion of 11 studies. The quality of these studies was assessed.
Within the identified studies, there was great variation in the specific type of family/family-based interventions
and disorders. According to the outcomes of the checklists, the overall quality of the economic evaluations was low.
Results varied by study. Due to the variations in setting, design and outcome it was not feasible to pool results using
a meta-analysis.
Conclusions: The quality of the identified economic evaluations of family/family-based therapy for treatment
of externalizing disorders, adolescent substance use disorders and delinquency was insufficient to determine
the cost-effectiveness. Although commonly applied, family/family-based therapy is costly and more research of higher
quality is needed.
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Background
Family therapy and family-based treatment is considered
an evidence-based practice treatment for children and
adolescents with externalizing disorders, symptoms of
delinquency and/or substance use disorder [1, 2]. Familial
and extra-familial systems are known to influence the
individual [3–7], and therefore family/family-based ther-
apy is not only aimed at the individual youth but also at
systems surrounding the individual. For instance, delin-
quency and substance abuse in adolescents have been
shown to be influenced by family factors, like parenting
style and attachment [3–7]. In addition, a recent review
indicated that problems within the extra-familial system,
like delinquent peers, problems with bonding at school
and in the neighborhood are risk factors for delinquency
and problem drinking [7]. As the individual, familial and
extrafamilial systems are interconnected, family/family-
based therapy not only positively affects the adolescent
but also the family (family cohesion) and the extra-familial
systems [8].
For the purpose of the present paper, family therapy
and family-based treatment is broadly defined as
treatments in which primarily family members and/or
members of the families’ wider networks are involved
in the treatment process of resolving problems for young
people [9] as opposed to treatments that mainly or solely
focus on the individual youth, or treatments that do not
focus on youths’ problem behavior, like marital therapy.
Well-known forms of family/family-based treatments
are Multisystemic therapy (MST) [10], Functional Family
Therapy (FFT) [11] and Multidimensional Family ther-
apy (MDFT) [12]. Although there is a large overlap be-
tween these types of therapies, there are also some
differences [13]. For instance, in FFT and MST there is
more focus on antisocial behavior. However, the degree
of severity of the disorder is often higher in MST com-
pared to FFT. More details of these differences are de-
scribed in Appendix 1.
Recently, Von Sydow et al. [1] systematically reviewed
studies on the effectiveness of family/family-based ther-
apy for the treatment of children and adolescents who
have externalizing disorders. Their study included disor-
ders like substance abuse, attention deficit hyperactivity
disorder, conduct disorder and symptoms of delin-
quency. They concluded that there is sound evidence
that family/family-based therapy is effective with par-
ticularly large effect sizes for delinquency and substance
abuse measures. However, in the meta analyses that were
included in Von Sydow’s systematic review, more cau-
tious conclusions regarding the effectiveness of systemic
therapy were drawn.
Current health care policy in the Netherlands and else-
where places emphasis on the provision of effective
mental health services in a cost effective way. Family/
family-based interventions are intensive as they consist
of a relatively high number of sessions per week and
subsequently are relatively expensive [14–16]. Therefore,
there is a need for economic evaluations to assess
whether additional effects gained through family/family-
based therapy in comparison to alternative treatments –
if observed – justify the additional costs. Morgan et al.
[17] described eight studies, analyzing the cost-
effectiveness of family-based treatments for substance
abusing adults and adolescents and concluded that some
of these treatments could be considered as cost-effective.
However, family based therapies like marital therapy,
were also included in this study. In addition, the litera-
ture search in this study was not systematically con-
ducted and was only considering patients with substance
use disorders. To our knowledge, no systematic review
of economic evaluations of family/family-based therapy
in externalizing, delinquent or substance-abusing adoles-
cents has yet been performed.
Hence, this paper presents a systematic review of
economic evaluations of systemic interventions in ado-
lescents with externalizing disorders, substance abuse or
delinquency. The aim of the present study was to assess
the evidence on cost-effectiveness of family/family-based
therapy for adolescents with externalizing disorders, sub-
stance use disorders or delinquency, and to evaluate the
quality of the existing studies, and the generalizability of
the study findings.
Methods
The review was performed according to the Cochrane
handbook for systematic reviews of interventions [18]
and adopted the Preferred Reporting for Systematic re-
views and Meta-Analyses (PRISMA) statement [19].
Search strategy
A systematic literature search was performed in Pubmed,
ERIC, Psycinfo and Cochrane reviews (including eco-
nomic trials and clinical trials). These different search en-
gines were used because of their high quality, coverage of
large databases and their focus on economic trials.
Search terms encompassed the different types of
systemic therapy (Functional Family Therapy, Multidi-
mensional Family therapy, Multidimensional Foster
Care, Multisystemic Therapy, Family Behavior Therapy
and Brief Strategic Therapy) but also more general classifi-
cations (systemic therapy, substance abuse treatment,
family based therapy, Family based intervention, Family
system intervention, Family intervention program). These
terms were searched for in title and abstract and were
then combined with terms referring to economic evalua-
tions searched for in title and abstract or a Medical Sub-
ject Headings (MeSH) term (economic evaluation, cost-
effectiveness, cost-utility, cost benefit, cost analysis, cost
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measure) and in the title (costs). Costs were searched for
only in the title, and not in the abstract, because the latter
resulted in many irrelevant studies. This search term was
included as we noticed that although in some studies both
costs and effects were evaluated, the main focus of these
studies was to evaluate the costs and a smaller part was
referring to the effects. Consequently, when only terms re-
ferring to both the costs and effects were included, these
studies would have been missed. The search term
“Economic modeling” was not explicitly incorporated into
the search strategy as the modeling should be part of a
cost-effectiveness, cost utility, cost benefit or cost analysis
(corresponding with our aim).
Abbreviations were also included. To improve our
search, MeSH terms were used, see Appendix 2 for more
details.
Selection strategy
In Fig. 1 the selection criteria are described and num-
bered. The criteria were applied to the studies in
chronological order and when a study was excluded
based on a criterion the number as shown in Fig. 1 was
noted. We considered studies from January 1990 until
January 2016. The selected study types were clinical/ran-
domized controlled trials (RCT), reviews, systematic re-
views and meta-analyses. The treatment needed to
consist of a family/family-based intervention, targeted at
adolescents (10–20 years old) with a substance use dis-
order, externalizing disorder or delinquent behavior. The
method needed to be a cost or cost- effectiveness/bene-
fit/ utility analysis. When studies were assessed for eligi-
bility based on their abstracts and it was likely that they
only contained cost-outcomes and no effect-outcomes,
they were also included. To determine the eligibility of
the full text articles, the same selection criteria were
used, except that accessibility of the study was a require-
ment (full text available) and studies that only contained
costs-outcomes and no effect-outcomes were excluded.
The selection of the articles was performed by two re-
searchers independently. Differences in selections were
discussed until consensus was reached.
Data extraction and risk of bias
The quality of the studies was assessed with the British
Medical Journal Checklist for authors and peer reviewers
of economic submissions [20] and the Consensus on
Health Economic Criteria (CHEC) list for assessment of
methodological quality of economic evaluations [21] as
recommended by the Cochrane reviews handbook [18].
We also consulted the critical appraisal of the studies by
the NHS Economic Evaluation Database (NHS EED)
structured abstract [18]. This is a database from Cochrane
library consisting of structured abstracts of economic eval-
uations of health care interventions. Full economic
evaluations were identified from a variety of sources and
assessed according to a set of quality criteria. Subse-
quently, detailed structured abstracts were produced. In
addition to the checklists, information about the eco-
nomic perspective of the study (health care, societal etc.),
design, country, follow-up, type of disorder, sample size,
study dropout, age, gender, type, duration and intensity of
intervention, time horizon, currency and price year, key
features of sensitivity analyses and the included cost types
were collected for the economic evaluation described in
the studies. In accordance with the suggestions in the
Cochrane handbook [18] five different biases of the indi-
vidual studies were addressed: selection bias, performance
bias, detection bias, attrition bias and reporting bias [18].
They were respectively addressed by assessing if patients
were properly balanced at baseline, patients and therapists
were blinded, outcome assessors were blinded, the
amount of dropout in the studies and by reading the pro-
tocols of the studies.
Results
A total of 731 articles met the search criteria. After removal
of duplicates and a first selection based on the abstracts, 51
studies matched the inclusion criteria. After assessment for
eligibility, 11 studies were selected (see Fig. 1).
Characteristics of the studies
An overview of the characteristics of the studies, partici-
pants and the interventions is shown in Table 1. Ten of
the eleven selected studies were published between 2003
and 2015 [22–31] and one study was published in 1996
[32]. Eight of the studies originated from the United
States (USA) [22–24, 27, 29–32]. Remaining studies
were initiated in Sweden [26], England [28] and Mexico
[25]. All studies were (based upon) randomized con-
trolled trials. Two pairs of studies [22, 24, 27, 29] were
each based on one sample. Most of the studies com-
pared a family/family-based intervention with care as
usual [23, 26, 28, 30–32]. MST was the most researched
intervention as it was investigated in eight studies
[23, 24, 26–28, 30–32]. In the Study of Borduin et al.
[31] Multisystemic Therapy for Problem Sexual Behavior
(MST-PSB) was investigated. MST-PSB is an adaptation to
MST aimed at the treatment of juvenile sexual offenders.
A description of the (non- family/family-based) compara-
tor interventions is shown in Table 2. The mean number
of sessions of the family/family-based interventions was
between 1 and 3 times a week and the mean duration of
treatment was between 12 and 31 weeks. The average
follow-up time was between 6 and 300 months (25 years);
only four studies followed patients for more than 1 year
[26, 28, 30, 31]. Two studies were outliers in respect to the
time horizon they used (8 years and 25 years) [30, 31].
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Fig. 1 PRISMA flow diagram [19]
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Table 1 Features of the studies, participants and the interventions
Study Features study Features participants Features intervention
Coun-try Follow-up
(months)
Design Disorder Sample
size
Completed
study
Age Sex
(% male)
Intervention Number
of sessions
per week
Treatment
duration
(weeks)I C I C I C I C I C
Schoenwald et al.,
1996 [32]
USA 6 AT RCT SUD 59 59 NS 16 79 MST CAU 2–3b 18–19
French et al., 2003 [22] USA 12a RCT SUD Trial 1:
102 564 16 81 MET/CBT5 0–1 6–7
96 16 86 MET/CBT12 0–1 12–14
102 16 84 FSN 1–2 12–14
Trial 2:
100 16 79 MET/CBT5 0–1 6–7
100 16 80 ACRA 1–2 12–14
100 16 85 MDFT 1–2 12–14
Sheidow et al., 2004 [23] USA 12 AT RCT PC 115 NS 13 67 MST CAU NS 16
Dennis et al., 2004 [29] USA 12 RCT SUD 564 Trial 1:
102 16 MET/CBT 0–1 6–7
96 16 5 0–1 12–14
102 16 MET/CBT 1–2 12–14
12
100 16 FSN 0–1 6–7
100 16 Trial 2: 1–2 12–14
100 16 MET/CBT 1–2 12–14
5
ACRA
MDFT
McCollister et al.,
2009 [24]
USA 12 RCT SUD 38 42 NS 1 1 84 81 DC FC NS1 NS1
38 5 5 84 DC +MST
43 15 4 DC +MST + CM
15
French et al., 2008 [25] MEX 7 RCT SUD 30 30 114 16 1 80 83 FFT group NS1 NS1
29 16 6 76 Joint
31 16 84 CBT
Olsson, 2010 [26] SW 24 RCT CD 79 77 NS 15 61 MST CAU NS 12–20
Sheidow et al., 2012 [27] USA 12 RCT SUD 38 4 29 33 15 83 DC FC NS1 NS1
38 2 29 DC +MST
43 37 DC+MST+CM
Cary et al., 2013 [28] ENG 30 RCT DEL 56 52 46 45 15 15 83 82 MST+ CAU 3 20
CAU
Dopp et al. (2014) [30] USA 300 RCT DEL 92 84 70 56 15 69 MST CAU 3–4 21
Borduin et al. (2015) [31] USA 107 RCT DEL 24 24 24 22 14 96 MST-PSB CAU 3 31
Legend: I intervention, C comparator, NS not stated, NS1 reference to non-accessible article, NA not applicable, USA United States of America, SW Sweden, ENG
England, MEX Mexico, SUD substance use disorder, CD conduct disorder, PC psychiatric crisis, MST multisystemic therapy, Joint combination of individual and
family therapy, group skill-focused psycho-education group intervention, IT individual treatment, MST-PSB MST for Problem Sexual Behavior, CAU care as usual, FSN
family support network, MDFT multidimensional family treatment, MET/CBT12 motivational enhancement treatment/cognitive behavior therapy, 12 sessions; MET/
CBT5 motivational enhancement treatment/cognitive behavior therapy, 5 sessions; ACRA adolescent community reinforcement approach, DC drug court with
community services, DC +MST drug court with multisystemic therapy, DC +MST + CM drug court with mst and enhanced with a contingency management
programs, FFT functional family therapy, FC family court with community services
aCost data was only collected only during 3–9 months
bThe intensity of the treatment was between 2 and 3 times a week; AT after treatment
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Six studies were aimed at adolescents with substance
use disorder [22, 24, 25, 27, 29, 32], one study investi-
gated adolescents with a conduct disorder [26], one
study adolescents at risk for continuing criminal activity
[28],one study adolescents who had experienced a psy-
chiatric crisis [23], another study adolescents who were
serious juvenile offenders [30] and one study aimed to
investigate juvenile sexual offenders [31]. The average
sample size of the 9 studies (with separate samples) was
178 (SD = 163) with a variation between 48 and 600
patients. Follow-up attrition, when registered, was low
(not more than 30 %). Average age at baseline was 15
(Standard Deviation (SD) = 1) years and between 61 and
96 % of the individuals were males.
Types of economic analyses included cost-effectiveness
analyses [23, 25, 27, 29], cost-benefit analyses [22, 26, 30, 31]
and cost offset analyses [28]. The difference between a cost-
offset and a cost-benefit analysis is often not well-explained.
A cost-offset analysis compares the monetary value of
resource use with the monetary value of costs reduced
by the intervention (usually health care costs). In
contrast to a cost-benefit analysis which also focusses
on other outcomes that are translated in monetary out-
comes (like translating number of life years gained to a
monetary value). In reality, cost-offset analysis is a
partial cost-benefit analysis because it compares the
cost of a program with the monetary value of a single
outcome (i.e., avoided future health care costs). In two
studies, the economic evaluation was not explicitly clas-
sified [24, 32].
Outcomes of the studies
Details of the interventions and outcomes of our ana-
lyses are described in Tables 3 and 4. Costs were indexed
until 2014.
Substance abuse
Six studies were identified which included adolescents that
were treated for substance abuse [22, 24, 25, 27, 29, 32].
Three of these studies considered costs and effects
[25, 27, 29] and three considered both costs and ben-
efits [22, 24, 32].
Studies considering costs and effects In the study of
French et al. [25] FFT was shown to be more cost-
effective than a skill-focused psycho-education group
intervention for treating substance use disorders and de-
linquency after the first 4 months. After 12 months no
such effect was observed. Therefore, after 12 months the
cost-effectiveness analysis reduced to a simple cost
minimization analysis. As only treatment costs were
considered (narrow perspective), the intervention with
the lowest intervention costs, in this case group therapy,
was considered to be economically beneficial. In another
study, Dennis et al. [29] computed cost-effectiveness ra-
tios and these ratios indicated that overall, the most
cost-effective interventions were Motivational Enhance-
ment Treatment/ Cognitive Behavior Therapy, 5 sessions
(MET/CBT5) and Motivational enhancement treatment/
Cognitive Behavior Therapy, 12 sessions (MET/CBT12)
when compared to Family Support Network (FSN) in
Trial 1 and Adolescent Community Reinforcement
Approach (ACRA) and MET/CBT5 when compared to
MDFT in Trial 2. Sheidow et al. [27], computed Average
Cost-Effectiveness Ratios (ACERS). ACERS only incorp-
orate the pre-post treatment effect of one single treat-
ment so treatments are not directly compared. Although
this study showed that Drug Court with community
services (DC) was more cost effective compared to
FC regarding substance use disorders and that the
addition of multi-systemic therapy (MST) resulted in
an economically more beneficial treatment, the treat-
ments were not directly compared [27].
Table 2 Descriptions of comparator interventions
FSN Cognitive behavioral sessions and motivation treatment
in combination with a family component.
MET/CBT5 Motivational component and a cognitive behavioral
component, to enhance motivation to change drug
abuse and to grow the skills to maintain and regulate
abstinence
MET/CBT12 MET/CBT5+ 7 sessions of CBT are added to the therapy.
FC Family court treatment with community services/
Appearance court 2 times a year/ outpatient alcohol
and drug abuse service from the local center of the
state’s substance abuse commission
DC Drug court treatment with community services/
Appearance court 1 time a week/ outpatient alcohol
and drug abuse service from the local center of the
state’s substance abuse commission and monitoring
drug abuse
CM Frequent in home screens for drug use, voucher
system contingent on clean screens, and drug
refusal training.
ACRA Identifying reinforces that are incompatible with
the drug use and to strengthen those
CAU Sheidow et al. [23]: admission to a psychiatric unit
and aftercare
Schoenwald et al. [32]: outpatient substance abuse
services
Olsson et al. [26]: Not described
Cary at al. [28]: Youth Offending Team (YOT)
Dopp et al. [30]; Individual Therapy (IT)
Borduin et al. [31]: Cognitive behavioral group therapy
and individual services (from local juvenile court)
FSN family support network, MET/CBT5 motivational enhancement treatment/
cognitive behavior therapy, 5 sessions, MET/CBT12 motivational enhancement
treatment/cognitive behavior therapy, 12 sessions; ACRA adolescent
community reinforcement approach, FC family court with community services,
DC drug court with community services, CM contingency management
programs, CAU care as usual
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Table 3 Studies that reported substance use disorders
Studies considering costs and effects of substance abuse
Dennis
(2004) [29]
Costs intervention and comparators (per episode of care per patient) (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT)
In trial 1 MET/CBT 5,MET/CBT 12 and FSN were compared. In trial 2 MET/CBT 5, ACRA and MDFT were
compared. Costs were collected with a program (DATCAP) which yields estimates such as the total annual
opportunity cost of treatment and the labor cost per client.
Difference cost
The difference in costs were not showed
in this study.
However, it was showed that the
differences were significant.MET/CBT 5 (trial 1):
€ 1,226
MET/CBT 12 (trial 1):
€ 1,305
FSN (trial 1):
€ 3,576
MET/CBT 5 (trial 2):
€1,716
ACRA (trial 2):
€ 1,551
MDFT (trial 2):
€ 2,205
Effects intervention and comparators (per patient) (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT) Difference effects
Met CBT 5 (trial 1)
Days of abstinence: 269
Recovery*: 28 %
Met CBT 12 (trial 1)
Days of abstinence: 256
Recovery: 17 %
MET FSN (trial 1)
Days of abstinence: 260
Recovery: 22 %
*Recovery is defined as having no use or abuse
dependence problems and living in the community
Met CBT 5 (trial 2)
Days of abstinence: 251
Recovery: 23 %
ACRA (trial 2)
Days of abstinence: 265
Recovery: 34 %
MDFT (trial 2)
Days of abstinence: 257
Recovery: 19 %
The difference in effects were not showed
in this study
However it was showed that the difference
was not significant.
Results Cost per day of abstinence:
Met CBT5 (trial 1): € 541
Met CBT 12: € 677
Met FSN: € 1,667
Costs per person in recovery
Met CBT5 (trial 1): € 4,360
Met CBT 12: € 41,172
Met FSN: € 16,651
Cost per days of abstinence:
MET/CBT5 (trial 2): € 991
ACRA: € 729
MDFT: € 1,143
Costs per person in recovery
MET/CBT5 (trial 2): € 7,337
ACRA: € 4,913
MDFT: € 12,970
French
(2008) [25]
Costs intervention per patient (FFT, Joint and CBT)
FFT:
Treatment costs: € 1,817
Joint:
treatment costs: € 2,847
CBT:
Treatment costs: € 1.439
Costs comparator per
patient (Group)
Group:
Treatment costs: € 990
Difference costs
The difference in costs were not showed
in this study
Effects intervention per patient (FFT, Joint and CBT)
FFT:
% days marijuana use 4 months: 25.3
%of days marijuana use 7 months:39.8
YSR delinquency score 4 months: 8.2
YSR delinquency score 7 months:9.2
Joint
% of days of marijuana use 4 months: 38.1
marijuana use 7 months:35.4
YSR delinquency score 4 months: 9.1
Effects comparator per
patient (Group)
Group
% of days of marijuana use
4 months: 54.8
marijuana use 7 months: 40.7
YSR delinquency score
4 months: 9.5
lYSR delinuency score
7 months: 9.4
Difference effects with regression model:
FFT versus group:
% days marijuana use after
4 months: −20.11*
% days marijuana use after
7 months: 4.87
YSR delinquency score
4 months: −0.60
YSR delinquency score
7 months: 0.15
Joint versus
group
Delinquency
score after 4
months: −0.50
Delinquency
score after 7
months: −1.50
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Table 3 Studies that reported substance use disorders (Continued)
YSR delinquency score 7 months:8.5
CBT
% of days marijuana use 4 months: 50.6
% of days marijuana use 7 months:51.8
YSR delinquency score 4 months: 10.2
YSR delinquency score 7 months:10.4
CBT versus group
% days marijuana use after 4
months: 4.76
% days marijuana use after 7
months: 18.27
YSR delinquency score 4
months: 0.38
YSR delinquency score 7
months: 0.42
Joint versus group
% days marijuana use after 4
months: −14.86
% days marijuana use after 7
months “-2.00
YSR delinquency score 4
months: −0.50
YSR delinquency score 7
months: −1.50
Results Group therapy was most cost-effective, none of the other therapies were significantly different in effect compared to group therapy. So the intervention with the
lowest costs was considered to be most cost-effective.
Sheidow
(2012) [27]
Costs Intervention (DC, DC +MST, DC +MST + CM)
Treatment costs DC: € 9,083
Treatment costs DC + MST: € 12,369
Treatment costs DC + MST + CM: € 12,859
Costs comparator (FC)
Treatment costs FC:
€ 3,679
Difference costs:
The difference in costs were not shown in this study
Effects intervention (DC, DC + MST, DC +MST + CM)
DC
Marijuana use (days): −16.65
Polydrug use (days): 1.41
Alcohol use (days): 0.49
Heavy alcohol use (days): 0.86
SRD status offenses (incidents): −7.24
SRD Theft (incidents): −3.28
SRD crimes against persons (incidents): −2.69
DC ±MST
Marijuana use (days): −30,17
Polydrug use (days): :-1.11
Alcohol use (days): 0.27
Heavy alcohol use (days): −0.45
SRD status offenses (incidents): −11.11
SRD Theft (incidents): −2.79
SRD crimes against persons (incidents): −3.90
DC ±MST ± CM
Marijuana use (days): −27.86
Polydrug use (days): −6.76
Alcohol use (days): −7.56
Heavy alcohol use (days): −4.13
SRD status offenses (incidents): −10.38
SRD Theft (incidents): −3.19
SRD crimes against persons (incidents): −2.4
Effects comparator (FC)
Marijuana use (days): −15,43
Polydrug use (days): 2.27
Alcohol use (days): 2.97
Heavy alcohol use (days): 0.76
SRD status offenses
(incidents): 9.22
SRD Theft (incidents): −5.54
SRD crimes against persons (incidents): 0.49
Difference effects:
The difference in effects were not showed in this study
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Table 3 Studies that reported substance use disorders (Continued)
Results ACERS were calculated; average costs/ difference between mean incidents before and after treatment (negative means inefficient)
FC DC DC +MST DC +MST + CM
Marijuana use:
Polydrug use:
Alcohol use:
Heavy alcohol use:
SRD status offenses:
SRD theft:
SRD crimes against persons:
€ 238
(215–262)
€ −1,619
(−8,8839–5,601)
€ −,1,239
(−6,546–5,601)
€ −4,857
(−10,632–918)
€ −400
(−1,206–398)
€ 663
(428–899)
€ −7,588
(−10,667–4,510)
€ 545
(474–617)
€ −6,425
(−27,541–14,692)
€ −18,814
(−42,034–4,405)
€ −10,535
(−28,804–7,733)
€ 1,254
(1,132–1,376)
€ 2,773
(−2.441–7,987)
€ 3,377
(2,976–3,777)
€ 410
(377–442)
€ 11,209
(−3,757–26,175)
€ −44,838
(−61,014–28,662)
€ 27,592
(−14,636–69,821)
€ 1,114
(907–1,321)
€ 4,428
(−1,224–10,081)
€ 3,175
(236–6,123)
€ 461
(434–488)
€ 1,912
(1,624–2,182)
€ 1,699
(1,486–1,912)
€ 3,109
(1,708–4,511)
€ 1,239
(1,009–1,496)
€ 4,032
(1,204–6,859)
€ 5,346
(4,723–5,968)
Studies considering costs and benefits of substance abuse
Schoenwald
(1996) [32]
Costs interventions (MST)
Mental health outpatient (total): €4,242
Mental health day treatment (total): € 5,423
Mental health residential treatment (total): €6,899
Psychiatric inpatient (total): €15,752
Psychiatric emergency room (total): €1,150
Substance abuse outpatient (total): € 2,001
Substance abuse residential treatment (total): €3,450
Substance abuse inpatient (total): € 16,098
Marine Institute day treatment (total): € 18,926
Marine Institute residential treatment (total): € 3,036
Treatment costs: € 266,516
Costs comparator (CAU)
Mental health outpatient
(total): € 19,075
Mental health day treatment
(total): € 1,118
Mental health residential treatment (total): €0
Psychiatric inpatient (total): €18,513
Psychiatric emergency room
(total): €3,450
Substance abuse outpatient
(total): € 20,272
Substance abuse residential treatment (total): €43,695
Substance abuse inpatient
(total): €93,771
Marine Institute day treatment (total): €28,618
Marine Institute residential treatment (total): €0
Benefits interventions
Incarceration days: €65,427
Benefits CAU
Incarceration days:
€120,851
Results MST: Total costs (costs + benefit) with incarceration = €408,919 and the total costs (costs + benefit) with incarceration per youth = €6,930
CAU: Total costs (costs + benefit) with incarceration = € 335,845 and the costs (costs + benefit) per youth = €5,693.
Difference in total between groups = €1,019
French
(2003) [22]
Costs interventions (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT) Benefits interventions (MET/CBT 5, MET/CBT 12, FSN,
ACRA, MDFT)
Treatment costs were measured Health service utilization; Outpatient clinic/doctor’s
office visit
Days bothered by health/medical problem
Substance-absue treatment utilization; Days in
detoxification program; Day in inpatient
treatment program; Day in long-term
residential program; Intensive outpatient program visits;
Regular outpatient program visits
Education and employment; Days missed at school
or training; Personal income; Days stressful for parents
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Table 3 Studies that reported substance use disorders (Continued)
Day missed of work or school by parent
Criminal activity; Arrests; Day on probation;
Days on parole; Days in prison/jail;
Days in juvenile detention
Incremental arm:
MET/CBT5:€ 1,226
MET/CBT12: € 1,305
FSN: € 3,576
Alternative arm:
MET/CBT5: € 1,716
ACRA: € 1,551
MDFT: € 2,216
Incremental arm:
MET/CBT5
Baseline € 2,553
3 months: € 2,133
6 months: € 1,671
9 months: € 945
12 months: € 1,217
MET/CBT12
Baseline: € 2,179
3 months: € 2,433
6 months: € 828
9 months: € 1,431
12 months: € 687
FSN:
Baseline: € 2,552
3 months: € 4,525
6 months: € 1,783
9 months: € 1,205
12 months: € 1,726
Alternative arm:
MET/CBT5
Baseline € 2,694
3 months: € 3,587
6 months: € 2,213
9 months: € 2,275
12 months: € 1,907
ACRA
Baseline: € 2,506
3 months: € 3,691
6 months: € 1,748
9 months: € 3,113
12 months: € 3,237
MDFT:
Baseline: € 2,019
3 months: € 3,938
6 months: € 1,467
9 months: € 2,573
12 months: € 2,098
Results Net economic benefits (benefits + costs) relative to baseline:
3 different models were administred; Model 1: only time dummies for each of the follow-up periods (as treatment conditions were not included, we did not show the results.
Model 2: time dummies and indicator variables for treatment condition.
Model 3: time and treatment variables withan indicator variable for site. The last specification added numerous demographic and environmental controls.
MET/CBT12:
Model 2: € −198 (349)
Model 3: € −171 (346)
Model 4: € −340 (334)
FSN:
Model 2: € 607* (343)
Model 3: € 653 (340)
Model 4: € 250 (333)
*p < 0.1
Acra:
Model 2: € 369 (436)
Model 3: € 530 (430)
Model 4: € 554 (405)
MDFT
Model 2: −€ 61 (441)
Model 3: € 128 (436)
Model 4: € 100 (530)
McCollister
(2009) [24]
Costs interventions (DC, DC/MST, DC) Costs comparators (FC) Benefits interventions
(DC, DC/MST, DC)
Benefits comparators
(FC)
Treatment costs Treatment costs Criminal activity costs according to
Self-reported criminal activity (SRD):
DC:
€ 28.601 (94.314)
DC/MST:
€65.640 (240.559)
DC/MST/CM:
€80.222 (336.461)
Self-reported
criminal activity
(SRD):
FC:
€ 206.045 (545.581)
DC:
€8,156
DC/MST:
€11,547
DC/MST/CM:
€ 11,547
FC:
€3,304
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Table 3 Studies that reported substance use disorders (Continued)
Results After 12 months, total costs relative to FC with multivariate model (intervention costs not incorporated):
DC: € -124,877 (−84,107)
DC/MST: €-117,918 (−82,570)
DC/MST/CM: €140,274 (/79.066)*
All DC conditions generated reduction in crime costs, greater than average costs of treatment.
Currency and price year: Sheidow (2004).USD, 1997; Dennis (2004).USD, 1999; French 2008.USD, 1998; Sheidow (2012).USD 2004. When a price year was not stated it was estimated by taking the mean year of the
study duration or when not available subtracting 1 from the year of publication of the study
MST multisystemic therapy, Joint combination of individual and family therapy, group skill-focused psycho-education group intervention, CAU care as usual, FSN family support network, MDFT multidimensional family
treatment, MET/CBT12 motivational enhancement treatment/cognitive behavior therapy, 12 sessions, MET/CBT5 motivational enhancement treatment/cognitive behavior therapy, 5 sessions, Acra adolescent community
reinforcement approach, DC drug court with community services, DC +MST drug court with multisystemic therapy; DC +MST + CM drug court with MST and enhanced with a contingency management programs, FFT
functional family therapy, FC family court with community services, ACERS average cost-effectiveness ratios
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Table 4 Studies considering externalizing disorders and delinquency
Studies considering both costs and effects
Sheidow
(2004) [23]
Costs intervention (MST)
Medicaid (government insurance program)
costs (inpatient, Outpatient, Pharmacy,
other costs),
Other treatment costs paid for by study
MST
Medicaid costs: 0-end treatment
(4 months): €9,311
(±7,755)
Medicaid costs: End treatment-12 months:
€13,237 (±15,144)
Other treatment costs paid for by
study: €11,617
Costs comparator (CAU)
Medicaid (government insurance program)
costs (inpatient, Outpatient, Pharmacy,
other costs), Other treatment costs
paid for by study
CAU
Medicaid costs: 0-end treatment (4 months):
€13,255 (±5,762)
Medicaid costs: End treatment-12 months:
€15,207 (±18,485)
Other treatment costs paid for by study: €0
Difference costs (CostsCAU-CostsMST) (after risk adjusted model):
0-end treatment (total costs):
End treatment- 12 months
post-treatment (total costs):
-€ 1,828
-€452 (SE = 14)
Effects intervention
CBCL: Externalizing scores,
internalizing scores:
GSI: Global severity index are measures
The main effects were not showed
in this study but only differences over
time were presented.
Effects comparator
CBCL: Externalizing scores,
internalizing scores:
GSI: Global severity index
The main effects were not showed in this
study but only differences over time were
presented.
Difference effects (EffectsCAU-EffectsMST) (after risk adjusted model):
0-end treatment:
end treatment- 12 months
post-treatment:
Externalizing:-14.75 (SE = 8.37)
Internalizing:-14.19 (SE = 9.26)
Global severity index: −0.03
(SE = 0.497)
Externalizing:3.29 (SE = 9.97)
Internalizing:-6.18 (SE = 9.67)
Global severity index: −0.37
(SE = 0.428)
Results ICER: 1 point improvement in externalizing scores for usual care was associated with a cost of €1,561. 1 point improvement in externalizing scores for MST was associated with a
costs of €404. After 12 months both treatments have comparable costs and externalizing scores.
Studies considering costs and benefits
Olsson4
(2010) [26]
Costs intervention (MST)
Treatment costs: € 10.789
Travel: € 53 (133)
Costs comparator (CAU)
Travel: €151 (225)
Benefits intervention (MST)
Psychosocial and behavioral effects: −
Social services (placement):
€ 31.947 (€65.869)
Social services (nonplacement):
€ 8.557 (19.459)
National board of institutional
care (rebate): € 3.009 (11.014)
National board of institutional
care (placements): € 3.593 (31.937)
Wider societal costs and benefit:
set to zero
Psychosocial and behavioral effects:
set to zero
Benefits comparator (CAU)
Program effects
Social services (Placement):
€ 36.707 (73.407)
Social services (nonplacement):
€ 14.914 (15.405)
National board of institutional
care (rebate): € 2.375 (9.949)
National board of institutional
care (placements): 0 (0) SEK
Wider societal costs and
benefit: set to zero
Results The net loss to society after two years is € 4.555
Cary
(2013) [28]
Costs interventions (MST + YOT)
Treatment costs:€ 3.013 (1.940)
Social worker: € 733 (446)
Reparation worker: € 100 (131)
Drugs worker: € 54 (74)
Connexions worker: € 33 (69)
Parenting worker: € 36 (137)
Costs comparator (YOT)
Social worker: € 1.023 (779)
Reparation worker: € 83 (14)
Drugs worker: € 78 (152)
Connexions worker: € 18 (61)
Parenting worker: € 90 (182)
Group worker: € 22 (44)
Benefits interventions (MST + YOT) Benefits comparator (YOT)
Offending behavior (Young offender information system):
€ 12,397 (18 472) € 15,409 (24,013)
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Table 4 Studies considering externalizing disorders and delinquency (Continued)
Group worker: € 17 (34)
Psychologist: € 17 (67)
Other appointments:€ 20 (59)
Psychologist: € 30 (91)
Other appointments: € 26 (95)
Results Difference (Costs + benefits) between treatments € 1.612 (95 % C.I-€ 7.699-€ to 10.924)
In the cost-effectiveness plane, we see, there is 63 % probability that the net benefit of MST + Yot is positive in favor of the MST + YOT group.
Dopp
(2014) [30]
Costs interventions (MST)
Costs per patient: € 9,756
Costs comparator (CAU)
Costs per patient: € 1,843
Benefits intervention (MST) Benefits comparator (IT)
Benefits for taxpayer
Murder: € 0
Sexual offenses: € 922
Robbery: € 188
Assault: € 1.156
Property: € 2.395
Drug: € 916
Theft: € 131
Stolen property: € 24
Fraud: € 259
Assault: € 236
Drug: € 777
TOTAL: € 7.007
Benefits for taxpayer
Murder: € 0
Sexual offenses: € 602
Robbery: € 308
Assault: € 1.697
Property: € 1.899
Drug: € 1.334
Theft: € 188
Stolen property: € 53
Fraud: € 224
Assault: € 294
Drug: € 598
TOTAL: € 7.197
Results Crime victim avoided expenses
Murder/manslaughter
Tangible: € 6.125
Intangible: € 11.365
Sexual
Tangible: € 259
Intangible: € 3.439
Robbery
Tangible: € 575
Intangible: € 1.422
Assault
Tangible: € 539
Intangible: € 2.926
Property
Tangible: € 3.914
Intangible: € 0
Drug
Tangible: € 0
Intangible: € 0
TOTAL
Tangible: € 11.412
Intangible: € 19.151
Net present values and benefit-cost ratios
Net present value
Referred youths
Taxpayer: € 2.348
Crime victim tangible: € 2.389
Crime victim intangible € 9.375
Cumulative: € 29.939
Siblings:
Taxpayer: € 674
Crime victim tangible: € 2.702
Crime victim intangible: € 4.533
Cumulative: € 6.561
Sibling pairs
Taxpayer: € 1.399
Crime victim tangible: € 3.499
Crime victim intangible: € 11.238
Cumulative*: € 31.962
*: Includes the incremental costs of
MST over IT
Benefit cost ratio
Referred youths
Taxpayer: 1.3
Crime victim tangible: 1.3
Crime victim intangible 2.19
Cumulative: 4.78
Siblings:
Taxpayer: -
Crime victim tangible: -
Crime victim intangible: -
Cumulative: -
Sensitivity analysis
Max (plausible) values
Crime victim intangible benefits: € 48.087
Sibling juvenile arrest rates: € 30.74
Discount rates: € 24.063
Min (plausible) values
Crime victim intangible benefits: € 17.561
Sibling juvenile arrest rates:-
Discount rates: € 36.704
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Table 4 Studies considering externalizing disorders and delinquency (Continued)
Sibling pairs
Taxpayer: 1.18
Crime victim tangible: 1.44
Crime victim intangible: 2.42
Cumulative*: 5.04
*: Includes the incremental costs
of MST over CAU
Borduin
(2015) [31]
Costs interventions (MST-PSB)
Costs per patient: € 10,566
Costs comparator (CAU)
Costs per patient: €4,610
Benefits intervention (MST-PSB)
Benefits for taxpayer
Murder: € 0
Sexual offenses: € 6.419
Robbery: € 2.189
Assault: € 0
Property: € 2.831
Drug: € 1.899
Theft: € 180
Stolen property€ 0
Fraud: € 91
Assault: € 250
Drug: € 512
TOTAL: € 14.371
Benefits comparator (CAU)
Benefits for taxpayer
Murder: € 0
Sexual offenses: € 15.756
Robbery: € 0
Assault: € 2.194
Property: € 3.790
Drug: € 518
Theft: € 65
Stolen property: € 39
Fraud: € 75
Assault: € 289
Drug: € 112
TOTAL: € 22.839
Crime victim avoided expenses
Murder/manslaughter
Tangible: € 41.048
Intangible: € 76.169
Sexual
Tangible: € 1.739
Intangible: € 23.044
Robbery
Tangible: € 3.850
Intangible: € 9.529
Assault
Tangible: € 3.612
Intangible: € 19.611
Property
Tangible: € 26.244
Intangible: € 0
TOTAL
Tangible: € 76.494
Intangible: € 128.353
Net present values and benefit-cost ratios
Net present value
Referred youths
Taxpayer: € € 79.891
Crime victim tangible: € 70.538
Crime victim intangible € 122.397
Cumulative*: € 284.739
Siblings:
Benefit cost ratio
Referred youths
Taxpayer: 14.41
Crime victim tangible: 12.84
Crime victim intangible 21.55
Cumulative: 48.81
*: Includes the incremental costs of
MST over CAU
Sensitivity analysis
Max (plausible) values
Crime victim intangible benefits: € 387.085
Discount rates: € 239.009
Posttreatment arrest rates: € 478.277
Min (plausible) values
Crime victim intangible benefits : € 188.217
Discount rates: € 311.107
Posttreatment arrest rates: € 91.673
Currency and price year: Schoenwald 1996.USD, 1996; French 2003. United States Dollar (USD), 1999; Mc Collister (2009). USD,2008; Olsson (2010) Swedish krona (SEK), 2007; Cary (2013). Pounds, 2008; Dopp (2014)
USD, 2012; Borduin (2015) USD, 2013. When a price year was not stated it was estimated by taking the mean year of the study duration or when not available subtracting 1 from the year of publication of the study.
For Schoenwald et al. (2006), 1996 was taken as prices year although the study was also published in 1996. This was because they already published their first study in 1996 (preliminary findings) and subsequently
probably the current study was conducted in 1996
MST multisystemic therapy, Joint combination of individual and family therapy, group skill-focused psycho-education group intervention, CAU care as usual, FSN family support network, MDFT multidimensional family
treatment, MET/CBT12 motivational enhancement treatment/cognitive behavior therapy, 12 sessions, MET/CBT5 motivational enhancement treatment/cognitive behavior therapy, 5 sessions, ACRA adolescent community
reinforcement approach, DC drug court with community services, DC +MST drug court with multisystemic therapy; DC +MST + CM drug court with MST and enhanced with a contingency management programs, FFT
functional family therapy, FC family court with community services, MST-PSB MST for sexual behaviors; ICER incremental cost-effectiveness ratio
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Studies considering costs and benefits Three of the
studies that considered adolescents with substance use
disorders, considered costs and benefits [22, 24, 32]. The
study of French et al. [22] indicated that MET/CBT-5,
MET/CBT-12 and FSN generated significant economic
benefits to society for substance abusing adolescents,
MDFT and ACRA did not generate these benefits.
MCcollister et al. [24] showed that the savings in costs off-
set the treatment costs of DC, especially for DC/MST/
CM, in juvenile drug court participants when compared
to FC (Family court with community services). Schoen-
wald [32] showed that the monetary benefits of MST com-
pared to CAU for substance use disorder almost offset the
higher costs of MDFT. Over time the difference between
benefits and costs may be reduced to a complete offset.
Delinquency/externalizing disorders
Five studies considered adolescents with delinquency or
externalizing disorders; the study of Sheidow et al. [23],
Olsson [26], Cary et al. [28], Dopp et al. [30] and Borduin
et al. [31] respectively included patients with a psychiatric
crisis, patients with a conduct disorder,delinquent adoles-
cents, serious juvenile offenders and juvenile sexual of-
fenders. One study, Sheidow et al. [23], considered both
costs and effects and four studies [26, 28, 30, 31] consid-
ered both costs and benefits.
Studies considering costs and effects In the study of
Sheidow et al. [23], MST was effective in the short term
(4 months) in terms of externalizing behavior compared
to care as usual for patients with psychiatric emergen-
cies. But MST appeared equally effective on the cost
measure over the long term (12 months).
Studies considering costs and benefits Olsson [26]
showed that for adolescents with conduct disorder
MST’s benefits did not offset the costs and that MST
was subsequently associated with a net loss to society.
The study of Cary et al. [28] showed that MST in com-
bination with CAU has a scope to generate cost savings
when compared to providing CAU alone. The cost-
benefit study of Dopp et al. [30] indicated that MST,
when delivered to serious juvenile offenders, produces
economic benefits well into adulthood. Borduin et al.
[31] showed that when juvenile sexual offenders are
treated with MST-PSB; this treatment can produce last-
ing economic benefits.
Quality of the studies
Only for one study [23] commentary was available from
the NHS-EED. We compared the commentary on the
study with our quality assessment checklists to evaluate
if all issues were addressed. The quality of the studies
was not only assessed for the 7 unique studies but for
the 9 studies. The argument for including all studies was
to differentiate between methods (e.g. analysis), display
of results and discussion even though they were based
on the same study. The quality assessed with the BMJ
checklist was between 52 and 86 % (Table 5). The quality
assessed with the CHEC list was between 50 and 79 %
(Table 5). Up to date, there are no thresholds (minimum
number of criteria satisfied) for these checklists to deter-
mine the difference between bad and good quality eco-
nomic evaluations [18]. Overall, the outcomes on the
checklists matched although quality assessed with the
CHEC list was consequently lower. The largest differ-
ence in quality percentages was 20 %. All studies clearly
stated their primary outcome measures. Most studies
did not report all relevant costs and effects.
Risk of bias
All studies were RCTs [22–32]. Two of these studies [23,
32] only included patients receiving Medicaid (an aid
program regarding insurances for low income families in
the United States). For these studies, the RCT of the effect
study contained (due to randomization) balanced samples.
However, these samples were not checked for balance
after the selection of participants who received medicaid,
so they were at risk for selection bias. All studies had a
high risk of performance bias, as blinding of both therap-
ist and patient is impossible. For two studies [23, 32]
blinding was not necessary as both the cost and out-
come data were extracted from existing data systems
(The medicaid billing records). Although blinding of out-
come assessors is possible to reduce detection bias, no
study reported to have done so. Blinding is also necessary
for pre-allocation assessment. All studies were based on
randomized controlled trials where allocation conceal-
ment is necessary. The studies included in this review, did
not explicitly refer to the allocation concealment. Three
studies were at risk of attrition bias. These three studies
did not describe the number of patients that dropped out
from the study [24, 27, 32]. Two studies only described
the overall attrition rate [22, 25]. For one study [29] how-
ever, overall attrition rate could be extracted by using the
study of French et al. [22] as it was based on the same par-
ticipants. Dropout in the effect-study of Sheidow et al.
[23] was low and although no dropout was described for
the economic evaluation, as the economic evaluation is
based on the same participants, this is expected to be low.
Overall, dropout rate (when measured) seemed low.
Reporting bias was assessed by reading protocols from the
studies and no bias was reported. Only for two stud-
ies [22, 29] a protocol existed. Other studies did not
have such a protocol, although for three studies trial
registrations were present [24, 27, 28]. There were no
indications of deviations from the original design. The
economic evaluations did not always include all clinical
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Table 5 Assessments of the quality of the studies with the Drummond checklist and the CHEC list
British Medical Journal Checklist 1a 2a 3a 4a 5a 6a 7a 8a 9a 10a 11a
1. The research question is stated. - - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓
2. The economic importance of the research question is stated. ✓ - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓
3. The viewpoint(s) of the analysis are clearly stated and justified. - ✓ - ✓ - - ✓ ✓ - - -
4. The rationale for choosing alternative programmes or
interventions compared is stated.
✓ - - - - - ✓ - ✓ - -
5. The alternatives being compared are clearly described ✓ ✓ ✓ ✓ - - - - ✓ ✓ ✓
6. The form of economic evaluation used is stated. - ✓ ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓
7. The choice of form of economic evaluation is justified in
relation to the questions addressed.
NC ✓ ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓
8. The source(s) of effectiveness estimates used are stated. ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
9. Details of the design and results of effectiveness study are
given (if based on a single study).
✓ NA ✓ ✓ ✓ ✓ ✓ ✓ - ✓ ✓
10. Details of the methods of synthesis or meta-analysis of
estimates are given (if based on a synthesis of a number of
effectiveness studies).
NA NA NA NA NA NA NA NA NA NA NA
11. The primary outcome measure(s) for the economic
evaluation are clearly stated.
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
12. Methods to value benefits are stated. ✓ ✓ NA ✓ ✓ NA ✓ NA ✓ ✓ ✓
13. Details of the subjects from whom valuations were
obtained were given.
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
14. Productivity changes (if included) are reported separately. NA ✓ NA NA NA NA NA NA NA - -
15. The relevance of productivity changes to the study
question is discussed.
- - - - - - ✓ - - - -
16. Quantities of resource use are reported separately from
their unit costs.
✓ ✓ - - - - - - ✓ ✓ ✓
17. Methods for the estimation of quantities and unit costs
are described.
- - - - ✓ - ✓ ✓ ✓ ✓ ✓
18. Currency and price data are recorded. ✓ ✓ - ✓ - - - ✓ ✓ ✓ ✓
19. Details of currency of price adjustments for inflation or
currency conversion are given.
✓ ✓ - - - - ✓ - ✓ ✓ ✓
20. Details of any model used are given NA ✓ ✓ ✓ ✓ ✓ NA NA ✓ NA NA
21. The choice of model used and the key parameters on
which it is based are justified.
NA - - ✓ - - NA NA - NA NA
22. Time horizon of costs and benefits is stated. ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
23. The discount rate(s) is stated. NA NA NA NA NA NA ✓ NA ✓ ✓ ✓
24. The choice of discount rate(s) is justified. NA NA NA NA NA NA ✓ NA ✓ ✓ ✓
25. An explanation is given if costs and benefits are not
discounted.
NA NA NA NA NA NA NA NA NA NA NA
26. Details of statistical tests and confidence intervals are
given for stochastic data.
- - ✓ - ✓ - ✓ ✓ ✓ - -
27. The approach to sensitivity analysis is given. ✓ - ✓ - - - ✓ NC ✓ ✓ ✓
28. The choice of variables for sensitivity analysis is justified. ✓ NA NA NA NA NA ✓ NA ✓ ✓ ✓
29. The ranges over which the variables are varied are justified. NC NA NA NA NA NA ✓ NA ✓ ✓ ✓
30. Relevant alternatives are compared. ✓ NC - NC ✓ NS ✓ ✓ ✓ ✓ ✓
31. Incremental analysis is reported. ✓ ✓ - ✓ ✓ - ✓ - ✓ ✓ ✓
32. Major outcomes are presented in a disaggregated as
well as aggregated form
✓ ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓
33. The answer to the study question is given. ✓ NC ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
34. Conclusions follow from the data reported. ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ - -
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outcomes that were available [23–26, 32] as there was often
only interest in specific outcomes. One study [25] excluded
clinical outcomes as there was no difference between treat-
ments in terms of outcomes and so only costs were consid-
ered (costs minimization). The exclusion of outcomes was
not related to possible negative impact on the results as
effects in the studies were equally or more beneficial when
compared to the effects of the comparator.
Methodological summary
Uncertainty around treatment costs was not presented in
four studies as averages of these costs were used [24, 27,
30, 31]. In six studies [22, 23, 25, 29–32] uncertainty
around the (other) estimates was not (fully) addressed. In
seven studies, a simple one way sensitivity analysis was
used to assess the impact that changes in a certain param-
eter will have on the conclusions [22, 23, 26, 28, 30–32].
In two studies, sensitivity analysis was applied by imputing
missing data in different ways. Outcomes proved to be
robust [27, 28]. Two studies performed scenario ana-
lyses meaning that cost estimates (surrounded by un-
certainty) were increased or decreased. Data proved to
be robust [26, 32]. In another study a sensitivity analysis
was carried out to assess the effect which outliers in each
therapy group had on outcomes, but this did not have an
effect the results. In the studies of Dopp et al. [31] and
Table 5 Assessments of the quality of the studies with the Drummond checklist and the CHEC list (Continued)
35. Conclusions are accompanied by the appropriate caveats. - - ✓ ✓ - ✓ ✓ ✓ - ✓ -
Total score British medical journal checklist 68 % 61 % 63 % 68 % 54 % 52 % 86 % 70 % 83 % 81 % 77 %
CHEC list
1. Is the study population clearly described? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
2. Are competing alternatives clearly described? ✓ ✓ ✓ ✓ - - - - ✓ ✓ ✓
3. Is a well-defined research question posed in answerable form? - - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓
4. Is the economic study design appropriate to the stated objective? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
5. Is the chosen time horizon appropriate to include relevant
costs and consequences?
NS NS ✓ NS NS NS ✓ NS NS ✓ ✓
6. Is the actual perspective chosen appropriate? - ✓ - - - - ✓ - - - -
7. Are all important and relevant costs for each alternative
identified?
- - NS - - - - - - ✓ ✓
8. Are all costs measured appropriately in physical units? ✓ ✓ - - - - ✓ - ✓ ✓ ✓
9. Are costs valued appropriately? ✓ ✓ - ✓ ✓ NS ✓ ✓ ✓ ✓ ✓
10. Are all important and relevant outcomes for each alternative
identified?
- - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓
11. Are all outcomes measured appropriately? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
12. Are outcomes valued appropriately? - ✓ ✓ ✓ ✓ ✓ - ✓ ✓ ✓ ✓
13. Is an incremental analysis of costs and outcomes of alternatives
performed?
✓ ✓ - ✓ ✓ - ✓ - ✓ ✓ ✓
14. Are all future costs and outcomes discounted appropriately? NA NA NA NA NA NA ✓ NA ✓ ✓ ✓
15. Are all important variables, whose values are uncertain,
appropriately subjected to sensitivity analysis?
✓ - - - - - ✓ - ✓ ✓ ✓
16. Do the conclusions follow from the data reported? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ - -
17. Does the study discuss the generalizability of the results to
other settings and patient/client groups?
- - ✓ - - ✓ ✓ ✓ - - -
18. Does the article indicate that there is no potential conflict of
interest of study researcher(s) and funder(s)?
- ✓ - - - - - - - - -
19. Are ethical and distributional issues discussed appropriately? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Total score CHECb 56 % 67 % 61 % 61 % 50 % 50 % 79 % 50 % 79 % 74 % 74 %
NS not stated, NA not applicable, NC not clear
Explanation criteria checklist: British medical journal checklist: 1. A specific question is not necessary, as long as the goal of the research is clearly stated; 5. The
competing alternatives may also be described in a different accessible paper from the RCT in more detail 10. The presentation of the results is clearly given and
discussions of the study contain generalizability and comparison with other studies. CHEC list: 5: Chosen time horizon is appropriate when after a certain time no
additional effects are attained
aStudies: Schoenwald et al., 1996; 2 French et al., 2003; 3 Sheidow et al., 2004; 4 Dennis et al., 2004; 5 McCollister et al., 2009; 6 French et al., 2008; 7 Olsson, 2010;
8 Sheidow et al., 2012; 9 Cary et al., 2013; 10 Dopp et al., 2014; 11. Borduin et al., 2015
bScores were calculated by dividing the positively checked items on the quality checklist by the total minus items on the checklist that were not applicable (NA)
to the study
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Borduin et al. [31] a sensitivity analysis was applied by
using plausible minimum and maximum values (obtained
from other studies) for offense categories, arrest rates and
discount rates. French et al. [22] used different models
which assessed the effect on using more or less covariates
in the models but it did not affect the results. In six of the
studies cost-effectiveness/utility/benefits were assessed
based on models [22–25, 28, 32]. Four of these studies
used simple regression models [23–25, 28] and two
used a more advanced least squares random effect
model [19, 26]. The remaining three studies did not
integrate any model in the analysis. Three studies did
not report their price year (the year to which costs
are indexed) [23, 24, 32].
Authors of three studies indicated that a societal per-
spective was adopted, where not only health care costs
but also other costs, for example those associated with lost
or impaired ability to work, were taken into account
[22, 26, 29]. However, this was only true for the study of
Olsson [26], as this was the only study to assess costs
outside the health care sector. In the studies of
Dennis et al. [29] and French et al. [22], the societal
part was defined as using market values for calculat-
ing the costs of goods and services used. Dopp et al.
[30] and Borduin et al. [31] conducted cost-benefit
analyses and did not explicitely mention their per-
spective. Both studies focused on taxpayer benefits
and expressed intagible benefits in monetary values.
Cary et al. [28] used a narrow perspective as only services
that were recorded by a specific data-system were in-
cluded (appointments with social workers, connexion
workers (a United Kingdom (UK) governmental informa-
tion, advice, guidance and support service for young
people aged thirteen to nineteen), reparation workers
(coordinates and supports a range of interventions and
community reparation projects that young people will
have to undertake as part of their Referral or Community
Order), parenting workers, group workers and psycho-
logists). Sheidow [23] adopted the perspective of an insti-
tution. Other studies did not explicitly state their
perspective. Most of the studies only reported treatment
costs. A summary of the costs and clinical outcomes mea-
sured in the studies is provided in Table 6.
Following Drummond et al. [33], full economic evalua-
tions should not only report costs, but also health out-
comes. Four studies were classified as cost-effectiveness
analyses [23, 25, 27, 29]. Only one of these studies com-
pared treatments using an incremental cost-effectiveness
ratio [29] as described for instance by Drummond et al.
[33]. The cost-effectiveness analysis of French et al. [25]
was reduced to a simple cost minimization analysis as
the effects of both treatments after analysis proved to be
similar. Sheidow et al. [27] calculated average cost-
effectiveness ratios (ACER), which means that there was
no direct comparison between treatments but only be-
tween the before- and after treatment costs and effects
of every participant. In four studies it was explicitly
stated that cost-benefit analyses [22, 26, 30, 31] were
performed. Olsson [26] considered psychosocial and be-
havioral effects, but as no difference was observed re-
garding these clinical measures between treatments,
these effects were excluded from the analysis. French et
al. [22] did not value the health outcomes on which the
intervention was focused (like reduction in days of sub-
stance use) but did value the effects of treatment on
education, employment and criminal activity. Dopp et al.
[30] and Borduin et al. [31] conducted a cost-benefit
analysis; the cost outcome were the treatment costs and
the benefits were defined as taypayer benefits, tangible
benefits and intangible benefits were expressed in mon-
etary values. Cary et al. [28] classified his study as a
cost-offset evaluation. He calculated the net-benefit, but
stated that his study cannot be viewed as a cost-
effectiveness study as he did not measure health out-
come. Two studies did not state the type of economic
analyses they performed [24, 32], but did consider both
costs and benefits. Mcollister [24] indicated that her
study was not a full economic evaluation, as she only
considered treatment costs. This is also the case con-
cerning the study of Sheidow et al. [27], however, this
study was stated to be a cost-effectiveness analysis. Fur-
thermore, Schoenwald et al. [32] did not classify their
study explicitly but considered both costs of different
health care services and monetary benefits so it can be
considered a cost-benefit analysis.
Limitation/generalizability summary
Four studies commented on their generalizability [23,
25–27]. Sheidow et al. [23] reported that as their sample
only consisted of youths enrolled in Medicaid, which are
generally economically less advantaged, findings cannot
be generalized to a more economically advantaged popu-
lation. The same is true, although not stated, for the
study of Schoenwald et al. [32] who also analyzed Me-
dicaid data. The study of Olsson [26] was conducted in
Sweden, where MST is twice more expensive than in the
USA and may play a different role in society. MST in
Sweden may be used as an alternative to nonplacement
interventions as opposed to an alternative to placement
interventions as found in other studies. Also in the study
of French et al. [25], which was conducted in Mexico, lo-
cation and small sample size were indicated as limita-
tions for generalizability. The same was true, although
not stated, for the study of Cary et al. [28] which was
conducted in the United Kingdom. Also an important
limitation (but not mentioned as such) were the omis-
sions of uncertainty around the estimates in the studies
of Dopp et al. [30] and Borduin et al. [31], so the results
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should be interpreted with caution. Furthermore, the
study of Borduin et al. [31] was based on a very
small (the smallest one in this review) sample size
(only 48 patients) so uncertainty around the esti-
mates (not reported) is expected to be high.
Sensitivity analysis is not a solution for this problem
as significance of the results cannot be determined
(as the estimates in the sensitivity analysis are also
subjected to uncertainty). The juvenile drug court
programs, analyzed in the study of Sheidow et al.
[27] are not easily generalized to other settings as
they show great variation due to absence of a strict
format. In addition, other settings may have different
populations and salaries implying differences in costs.
Almost all studies were cautious with drawing conclu-
sions on their data. They not only recognized limita-
tions within their research but also recognized that
the number of economic evaluations is very limited
and more research is needed before being able to
draw conclusions [22–28, 32].
Meta analysis
The data from the economic evaluations were not
pooled as the population, setting, outcomes, costs and
interventions were not comparable across studies.
Discussion
This systematic review summarized and evaluated the
cost-effectiveness of family/family-based therapy for
adolescents with externalizing disorders, substance
use disorder and delinquency. The overall quality of
these studies was low, they produced mixed results..
Research should consider a wider perspective and
take into account all relevant costs and effects using
sophisticated models. Studies evaluating family/family-
based therapy concerned various outcomes and costs,
and investigated a variety of treatments in various
populations in different settings. Therefore it was not
possible to conduct a meta-analysis.
As expected, most of the studies were conducted in
the United States where family/family-based treatments
originate from [10, 11, 34]. The findings cannot be easily
generalized to other health care systems as they differ
between countries. The quality assessments showed that
overall studies scored between 50 and 86 % and only
two studies scored higher than 80 % [26, 28, 30, 31].
Studies that were conducted more recently, were in gen-
eral higher of quality. When the two most recent studies
[30, 31] were not considered, the quality of the studies
overall was slightly higher for those studies originating
from Europe. The quality of the two most recent studies
was high when using the quality checklists, however,
they also contained some important limitations. Firstly,
although quality checklists only contain one question
with respect to uncertainty around the estimates, it can
be of paramount importance, especially when the sample
size is low. Secondly, these studies are not easily general-
ized to an European setting as they conducted cost-
benefit analyses, opposed to cost-effectiveness analyses
that are commonly applied in European studies.
Although the checklists used to assess quality of the
studies depend on the subjective evaluation of the
researchers and have yet not been validated, these two
checklists have received much scrutiny and are therefore
recommended [18]. Recommendations that follow from
the quality assessment of the studies that were included
in the review, are the following. Different treatments
that are included in the study should be described more
Table 6 Overview of costs and clinical outcome measures used in studies
Treatment costs Other healthcare
costs
Costs outside
health care sector
Perspective used in
the economic evaluations
Clinical outcome measure
(Schoenwald et al., 1996) [32] ✓ ✓ Healthcare -
(French et al., 2003) [22] ✓ Institution -
(Sheidow et al., 2004) [23] ✓ ✓ Healthcare CBCL/GSI
(Dennis et al., 2004) [29] ✓ Institution -
(McCollister et al., 2009) [24] ✓ Institution SRD
(French et al., 2008) [25] ✓ Institution YSR/days of marijuana use
(Olsson, 2010) [26] ✓ ✓ Societal -
(Sheidow et al., 2012) [27] ✓ Institution TLFB/SRD
(Cary et al., 2013) [28] ✓ Institution -
Dopp et al. (2014) [30] ✓ ✓ Societal -
Borduin et al. (2015) [31] ✓ ✓ Societal -
CBCL child behavior checklist, GSI global severity index, SRD self-report delinquency scale, TLFB timeline follow-back form, YSR youth self report
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clearly so the differences and similarities between treat-
ments are understandable. In many of the studies
included in the review, the perspective taken was not
mentioned or did not match with the categories of the
costs that were included. In line with guidelines for eco-
nomic evaluations the perspective should be stated [33].
A more broad perspective (societal versus healthcare)
is recommended. The unit costs and resource use
should be reported separately and a source of the
references for the unit costs should be given. It is
also important to explicitly mention whether a study
is considered a cost-effectiveness/cost-benefit or cost-
utility analysis.
Most studies included in the review used no model
or simple models (regression). More complex models,
like multilevel analysis, should be used. In this way
covariates can be included, correlation between
measurements over time can be addressed, missing
data is accounted for and skewness in the costs and
effects is considered. Uncertainty around costs should
also be presented by using for instance bootstrapped
costs/effects confidence intervals and can be visual-
ized in a cost-effectiveness plane. Sensitivity analysis
should be applied to variables that are uncertain (the
rationale behind it should be explained). A one way
sensitivity analysis is not always sufficient and a
sensitivity anaysis also taking into account interac-
tions between variables should be considered. A
common discount rate should be applied for all costs
and effects. Summary measures of the cost-benefit,
cost-effectiveness or cost utility should be given. In
case of a cost-effectiveness analysis incremental cost-
effectiveness ratio (ICERS) should be calculated. For
conducting economic evaluations it is advised to con-
sult a health economist.
Conclusions
Although family/family-based treatments are widely
used and can be considered as effective for the
treatment of a wide range of disorders [17], cost-
effectiveness also needs to be addressed. Taking cost-
effectiveness into account may have a large impact as
family/family-based treatments are expensive. This
review has summarized the economic evidence of
family/family-based therapy for substance use disor-
dersand delinquency in adolescents in a systematic
and transparent way by using state of the art guide-
lines [18, 19]. As there are few studies evaluating the
cost-effectiveness of family/family-based therapy and
the quality of the existing studies is limited, new
studies using higher quality standards are necessary.
Large-scale implementation of these treatment
models should be held back, until more evidence is
available.
Appendix 1
Appendix 2
Search terms Pubmed
1. “family therapy”[MESH]
2. “Functional family therapy”
3. (FFT NOT (“fast Fourier transform” OR “freedom-
from-transfusion” OR “fast Fourier transforms”
OR “fast Fourier transformation” OR “Far-Field
Transform”))
4. “Multisystemic Therapy”
5. (MST NOT (“microbial source tracking”
OR “minimum spanning tree”))
6. “Multidimensional Treatment Foster Care”
7. “MTFC”
8. “multidimensional family therapy”
9. “MDFT”
10. “family behavior therapy”
11. “FBT”
12. brief strategic family therapy”
13. “BSFT”
14. “family based therapy”[Title/Abstract]
15. “family based interventions”[Title/Abstract]
16. “family based intervention”[Title/Abstract]
17. “family systems intervention” [Title/Abstract]
18. “family systems interventions” [Title/Abstract]
Table 7 Description family/family-based interventions
Family/family-based interventions
MST Target family interaction and the extended social systems in
youths with substance abuse problems, delinquency or
antisocial behavior / Permits separate meetings adolescent
but preference for family /More focus on antisocial behavior/
focused both on family functioning and on extra familial
functioning / Treatment team not actively involved as
observers and actors but team is only self-reflexive/ Treatment
team actively involved as observers and actors /degree of
severity higher and combination of more problems
FFT Target family interaction and the extended social systems in
youths with substance abuse problems, delinquency or
antisocial behavior/ Almost no separate meetings adolescent
/More focus on antisocial behavior/More focused on family
functioning less on extra familial functioning/ Treatment team
not actively involved as observers and actors but team is only
self-reflexive/ explicitly emphasizes therapist is integral part of
the system/degree of severity lower
MDFT
Target family interaction and the extended social systems in
youths with substance abuse problems, delinquency or
antisocial behavior/ Separate meetings adolescent/ Focus on
substance abuse / focused both on family functioning and on
extra familial functioning /Treatment team not actively
involved as observers and actors but team is only self-reflexive/
degree of severity higher
Sources: Leukehof et al. and Oudhof et al. (Leukefeld et al., 2008;
Oudhof et al., 2009)
MST multisystemic therapy, FFT functional family therapy, MDFT
multidimensional family treatment
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19. “family system intervention” [Title/Abstract]
20. “family system interventions” [Title/Abstract]
21. “family intervention program”[Title/Abstract]
22. “family intervention programs”[Title/Abstract]
23. “systemic Therapy” [Title/Abstract]
24. OR 1–23
25. “economic evaluation” [title/Abstract]
26. “economic evaluations” [title/Abstract]
27. “cost effective” [title/Abstract]
28. “cost effectiveness” [title/Abstract]
29. “cost utility analysis” [title/Abstract]
30. “costs” [Title/Abstract] AND “effect”[Title/Abstract]
31. “cost” [Title/Abstract] AND “effect”[Title/Abstract]
32. “cost” [Title/Abstract] AND “effects”[Title/Abstract]
33. “costs” [Title/Abstract] AND “effects”[Title/Abstract]
34. “costs”[Title/Abstract] AND “benefits”[Title/Abstract]
35. “cost” [Title/Abstract] AND “benefit”[Title/Abstract]
36. “costs” [Title/Abstract] AND “benefit”[Title/Abstract]
37. “cost” [Title/Abstract] AND “benefits”[Title/Abstract]
38. “costs” [Title/Abstract] AND “utility”[Title/Abstract])
39. “cost” [Title/Abstract] AND “utility”[Title/Abstract])
40. “cost” [Title/Abstract] AND “utilities”[Title/Abstract]
41.“costs” [Title/Abstract] AND “utilities”[Title/Abstract])
42. “Cost Analysis” [title/Abstract]
43. “Cost Measures” [title/Abstract]
44. “cost benefit analysis”[title/Abstract]
45. “cost measure” [title/Abstract]
46. “cost” [title]
47. “costs” [title]
48. “cost benefit analysis” [MESH]
49. OR 25–48
50. NOT (cancer[Title/Abstract]OR psoriasis[Title/
Abstract]OR “radiation therapy”[Title/Abstract] OR
diabetes[Title/Abstract] OR diabetic[Title/Abstract]
OR obesity [Title/Abstract] OR aids[Title/Abstract]
OR HIV[Title/Abstract] OR sarcomas[Title/Abstract]
OR chemotherapy[title/Abstract]))
51. 24 AND 49 AND 50
Search terms Eric, Psycinfo and Cochrane
In Eric, the same search terms were used except for
the MESH terms. In psycinfo, the MESH terms were re-
placed with APA’s thesaurus of Psychological index
Terms and in cochrane, the same terms were used.
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